Loading...
Please wait, while we are loading the content...
Similar Documents
Pretreatment CA 15-3 levels do not predict disease-free survival in patients with advanced epithelial ovarian cancer.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Gemer, Ofer Oustinov, Natalia Gdalevich, Michael Dubnik, Serge Levy, Roni N. Yachnin, Adela Lavie, Ofer Baruch, Noa Ben Arie, Alon Ben |
| Copyright Year | 2013 |
| Abstract | AIMS To evaluate the role of pretreatment CA 15-3 levels as a predictor of disease-free survival in patients with advanced epithelial ovarian cancer. METHODS A cohort of 65 patients with FIGO stage III or IV epithelial ovarian cancer was evaluated. Patients were treated either with primary cytoreductive surgery followed by adjuvant platinum-based chemotherapy or with neoadjuvant chemotherapy with interval debulking surgery. All patients had pretreatment CA 15-3 and CA 125 tumor marker determinations. The patients were divided into a group with elevated CA 15-3 and a group with normal levels. The two groups were compared with regard to clinical and survival measures. RESULTS The patients' median age was 65 years (range, 37-90); 34 (52%) were at stage III and 31 (48%) at stage IV. CA 15-3 was elevated (>30 units/mL) in 44 (68%) patients, with a median level of 39 units (range, 4-2282). CA 125 was elevated (>35 units/mL) in 61 (94%) patients, with a median level of 947 units (range, 4-30,642). CA 125 and CA 15-3 levels were not correlated (r = 0.015, P = 0.332). The median follow-up was 22 months (range, 3-120 months). Fifty-three (81%) patients had disease recurrence and 43 (66%) died. Survival analysis showed that patients with elevated and normal CA 15-3 levels had similar recurrence-free survival (P = 0.78) and overall survival (P = 0.55). CONCLUSIONS Although elevated in the majority of patients with advanced epithelial ovarian cancer, CA 15-3 levels are not predictive of survival. |
| Starting Page | 6067 |
| Ending Page | 6078 |
| Page Count | 12 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://vecchiosito.istitutotumori.mi.it/istituto/documenti/rivistatumori/2013_02/22-Gemer%20(257-260).pdf |
| PubMed reference number | 23748823v1 |
| Alternate Webpage(s) | https://doi.org/10.1700/1283.14201 |
| DOI | 10.1700/1283.14201 |
| Journal | Tumori |
| Volume Number | 99 |
| Issue Number | 2 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Addison Disease Adjudication Calcium Cessation of life Epithelial ovarian cancer Follow-Up Report Hippocampus (Brain) Mucin-1 protein Neoadjuvant Therapy Neoplasms Overall Survival Patients Pharmaceutical Adjuvants Platinum Stage level 3 Tumor Debulking Tumor Markers ovarian neoplasm stage IV childhood Hodgkin's lymphoma |
| Content Type | Text |
| Resource Type | Article |
